Golden has been acquired by ComplyAdvantage.Read about it here ⟶

Avalon GloboCare

Avalon GloboCare is a cell Therapeutics & Technology.

Overview Structured Data Issues Contributors Activity

All edits by Robert Isaev

Edits on 16 Apr, 2022

Robert Isaev

edited on 16 Apr, 2022

Edits made to:

Table (+1 rows) (+2 cells) (+39 characters)

Table

Name

Role

Social link

Luisa Ingargiola

Chief Financial Officer

Robert Isaev

edited on 16 Apr, 2022

Edits made to:

Table (+1 rows) (+2 cells) (+30 characters)

Table

Name

Role

Social link

Meng Li

Chief Operating Officer

Robert Isaev

edited on 16 Apr, 2022

Edits made to:

Table (+1 rows) (+2 cells) (+56 characters)

Table

Name

Role

Social link

David Jin, M.D., Ph.D.

Chief Executive Officer, President

Robert Isaev

edited on 16 Apr, 2022

Edits made to:

Article (+323 characters)

Article

Avalon’s subsidiary and joint venture structure contribute to investor flexibility and R&D focus, enabling Avalon to establish our leading role in the fields of immune effector cell therapy (including CAR-T and CAR-NK), exosome-based regenerative therapeutics (our ACTEXTM platform), as well as "liquid biopsy" diagnostics.

Robert Isaev

edited on 16 Apr, 2022

Edits made to:

Article (+196 characters)

Article

Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth, development, as well as competitiveness in healthcare and CellTech industry markets.

Robert Isaev

edited on 16 Apr, 2022

Edits made to:

Article (+98 characters)

Article